Hantel, Andrew http://orcid.org/0000-0001-9612-3643
Cernik, Colin
Uno, Hajime
Walsh, Thomas P.
Calip, Gregory S. http://orcid.org/0000-0002-7744-3518
DeAngelo, Daniel J. http://orcid.org/0000-0001-7865-2306
Lathan, Christopher S.
Abel, Gregory A. http://orcid.org/0000-0003-1100-2813
Funding for this research was provided by:
American Cancer Society (Real World Innovation Award, Real World Innovation Award)
U.S. Department of Health & Human Services | NIH | Office of Extramural Research, National Institutes of Health (K08 CA273043)
American Society of Clinical Oncology (Career Development Award)
Article History
Received: 2 November 2023
Revised: 28 November 2023
Accepted: 1 December 2023
First Online: 21 December 2023
Competing interests
: AH reports receiving personal fees (advisory boards) from AstraZeneca and AbbVie outside the submitted work. GSC reports employment by Flatiron Health, an independent affiliate of the Roche group at the time the study was conducted, and current employment by AbbVie. CSL reports receiving personal fees (advisory boards) from BMS outside the submitted work. DJD reports receiving research funding from Abbvie, Novartis, Blueprint, and Glycomimetrics and personal fees (consulting) from Amgen, Autolus, Blueprint, Gilead, Incyte, Jazz, Kite, Novartis, Pfizer, Servier, and Takeda outside the submitted work. GAA reports receiving personal fees (consulting) from Novartis outside the submitted work.